PFE catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 2, 2026Sponsor estimate | NCT07029711A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataPfizer · Severe Alopecia Areata | PFELead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Dec 30, 2026Sponsor estimate | NCT05909397Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerPfizer · Breast Cancer | PFELead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT05059522Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingPfizer · Advanced Malignancies | PFELead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 2, 2026Sponsor estimatePhase 3NCT07029711A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataPfizer · Severe Alopecia AreataActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT05909397Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerPfizer · Breast CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT05059522Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingPfizer · Advanced MalignanciesActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 18, 2027Sponsor estimate | NCT05035212Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Pfizer · Lower Respiratory Tract Illness | PFELead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Jan 29, 2027Sponsor estimate | NCT05911295Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Seagen, a wholly owned subsidiary of Pfizer · Urothelial Carcinoma | PFELeadMRKCollaborator | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 18, 2027Sponsor estimatePhase 3NCT05035212Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Pfizer · Lower Respiratory Tract IllnessActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 3NCT05911295Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Seagen, a wholly owned subsidiary of Pfizer · Urothelial CarcinomaActive, not recruitingPFELeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.